Intellia Therapeutics

$34.28
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.94 (+6.00%) Today
$0.00 (0.00%) As of 5:15 PM EST after-hours

Why Robinhood?

You can buy or sell NTLA and other stocks, options, and ETFs commission-free!

About NTLA

Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. It provides scientific expertise, clinical development, and intellectual property position to unlock broad therapeutic applications of CRISPR or Cas9 genome editing and develop a potential new drug class. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA. The listed name for NTLA is Intellia Therapeutics, Inc. Common Stock.

CEO
John M. Leonard
Employees
270
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
2.03B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.05M
High Today
$34.69
Low Today
$32.40
Open Price
$32.92
Volume
1.02M
52 Week High
$35.54
52 Week Low
$9.18

Collections

NTLA Earnings

-$0.69
-$0.46
-$0.23
$0.00
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Feb 25, Pre-Market

You May Also Like